24th Dec 2008 12:19
This announcement replaces the original announcements released on 16 April 2008 at 12.27 and 12.29 (RNS Nos: 4764S and 4765S); 17 July 2008 at 17.32 (RNS No: 3515Z); and 15 October 2008 at 16.40 and 16.41 (RNS Nos: 9464F and 9469F).
The Administrators of both the GlaxoSmithKline Performance Share Plan and the SmithKline Beecham Medium Term Incentive Plan (the "Plans") notified the Company on 23 December 2008 of corrections to the market prices of Ordinary share ADRs used to calculate the number of shares reinvested for the participants of the Plans detailed in the affected original announcements under the dividend reinvestment element of those Plans for dividends paid to shareholders on 10 April 2008 and 9 October 2008. Accordingly, the market prices of ADRs stated in respect of dividends paid to shareholders on 10 April and 9 October 2008 should have read $43.87, rather than $43.84, and $37.19, rather than $35.41, respectively; and the participants' increased interests in Ordinary share ADRs have been corrected.
Details in respect of JP Garnier are excluded from these replacement announcements as he is no longer a director of the Company.
Save as disclosed above, all other details remain unchanged.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 15 April 2008 of an increase in their interests in Ordinary share ADRs at a price of $43.87 per ADR following the re-investment of the dividend paid to shareholders on 10 April 2008.
|
Mr D J Phelan |
235.28 |
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
16 April 2008
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and Mr Phelan on 16 July 2008 of an increase in his interests in Ordinary share ADRs at a price of $48.40 per ADR following the re-investment of the dividend paid to shareholders on 10 July 2008.
|
Mr D J Phelan |
178.82 |
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
17 July 2008
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and Mr Phelan on 14 October 2008 of an increase in his interests in Ordinary share ADRs at a price of $37.19 per ADR following the re-investment of the dividend paid to shareholders on 9 October 2008.
|
Mr D J Phelan |
235.50 |
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
15 October 2008
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company and the under-mentioned persons on 15 April 2008 of an increase in their interests in Ordinary share ADRs at a price of $43.87 per ADR following the re-investment of the dividend paid to shareholders on 10 April 2008.
|
Mr E J Gray |
16.55 |
|
Mr D J Phelan |
501.65 |
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
16 April 2008
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company and the under-mentioned persons on 14 October 2008 of an increase in their interests in Ordinary share ADRs at a price of $37.19 per ADR following the re-investment of the dividend paid to shareholders on 9 October 2008.
|
Mr E J Gray |
16.56 |
|
Mr D J Phelan |
502.13 |
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
15 October 2008
Related Shares:
Glaxosmithkline